Global Antibody Drug Conjugate Market- INTRODUCTION
The Antibody-Drug Conjugates (ADCs) Market is comprised of sales of Antibody-Drug Conjugates (ADCs). Antibody-drug conjugates (ADCs) are complexly manufactured therapeutics that consist of monoclonal antibodies, directed towards the tumour-associated antigens, which highly influence cytotoxic agents that are attached using chemical linkers.
The hurdles involved in the manufacturing of ADC act as restrictions on the antibody-drug conjugate market. ADC manufacturing requires a high capital investment and extensive specialized training for operators.
ADC development is a complicated process because it bees in a need of optimization of additional processing steps which are unpresented in conventional monoclonal antibody manufacturing. For example, the antibody-drug conjugation reaction and subsequent drug substance purification. Also, antibody-drug conjugates should be made in aseptic environments and the working person should be protected from the highly toxic drug compounds, which may cause operational problems and complications.
Manufacturers of antibody-drug conjugates are vigorously collaborating with other companies to share technology, product knowledge, resources and expand the business. In March 2019, AstraZeneca signed an agreement with commercialization collaboration and Global Development with Daiichi Sankyo Company for becoming the sole manufacturer of the antibody-drug conjugate Trastuzumab Deruxtecan (DS-8201).
In April 2019, Shanghai Microgen agreed with the Netherlands based Synaffix to use its tools for manufacturing antibody-drug conjugates. As per the deal, Microgen licenced two platforms from Synaffix which will boost the product growth.
Download a Free Sample Copy of Antibody Drug Conjugate Market @ https://wemarketresearch.com/sample-request/antibody-drug-conjugates-market/132/
Global Antibody Drug Conjugate Market- Overview
Antibody Drug Conjugates Market are thoroughly effective Biopharmaceutical medications designed as a targeted therapy for cancer treatment. ADCs are outlined to abolish cancer cells without causing any harm to the normal cells. This is a great advantage of ADC’s, how the unharmed healthy cells make patients recover quicker.
There is an increase in the commonness of cancer worldwide due to an unhealthy urban lifestyle and the urge to consume tobacco and alcohol proves to be a risk factor in the growing cases of cancer.
According to National Cancer Institute, “people or patients living beyond the predicted time of diagnosed cancer will approximately reach 19 Million by 2024.”
Demand for quality cancer treatment and cost-effectiveness is also expected to hike the ADC’s market growth rate.
Global Antibody Drug Conjugate Market- Forecast Period
The Antibody-Drug Conjugates Market is estimated at $1,387 Million and is expected to reach $3,198 Million by 2023, at a CAGR of 12.9% from 2022 to 2030.
Manufacturers of antibody-drug conjugates are looked upon by various regulatory bodies such as the Food and Drug Administration in the USA.
In the US, there is no particular guidance to industry on ADC development and the FDA follows the already existing guidelines for monoclonal antibodies and small drugs to regulate ADC.
The product quality offices at the FDA such as the Office of Biotechnology Products (OBP) or the Office of Pharmaceutical Quality mainly focus on the manufacturing of the antibody component of the ADC and the drug substance (DS), the control strategy for the antibody intermediate, and drug product (DP).
Small molecule review groups in the Office of Pharmaceutical Quality hold the primary responsibility for reviewing the fairness of the aspects of the control strategy, payload and linker and conjugate reaction.
Primary Market Players for the Global Antibody Drug Conjugate Market:
- Bayer AG
- Pfizer Inc.
- Seattle Genetics Inc.
- Oxford Biotherapeutics
- Abbive Inc.
- Takeda Pharmaceutical Company Limited
- Agensys Inc.
- Hoffman-La Roche Ltd.
- Immunomedics Inc.
Global Antibody Drug Conjugate Market Segmentation
The Antibody Drug Conjugate Market is based on drugs, mechanism of action, application, technology and region. Based on drugs, the market is classified into Adcetris and Kadcyla. Based on the mechanism of action, the market is separated into CD30 antibodies and HER2 antibodies. Based on application, the market is categorized into breast cancer, lymphoma. . By region it is analysed through the countries across North America, Europe, Asia-Pacific, and LAMEA.
Segmentation on the basis of Drugs
- Kadcyla
- Adcetris
Segmentation on the basis of Mechanism of Action
- HER2 Antibodies
- CD30 Antibodies
Segmentation on the basis of Application
- Lymphoma
- Breast Cancer
For More Details, Visit Our Report Page:https://wemarketresearch.com/reports/antibody-drug-conjugates-market/132/
Due to unhealthy lifestyle of people across the globe there is steep rise in prevalence of cancer and cancerous diseases. Additionally, surge in tobacco consumption through geographies posing the risk of cancer. As per the report by National Cancer Institute, the number of people existing beyond diagnosis is expected to extend up to 19 million by 2024.
Advancement medical technology is expected to propel the development of the market.
Technological advancement has played a very vital role the in growth of medical sector. Novel discoveries with regards to treatment, cure research, in the medical industry is expected to boost the market growth. Technological advancement has made medical care very much accessible to common public. Rising research activities in the oncology sector and growing association with research institutes is fuelling the growth.
COVID-19 impact on the market
Bereavement, isolation, loss of income and fear are triggering mental health conditions or exacerbating existing ones. These are the effects of recent Covid- 19 pandemic that had a calamitous impact on overall supply chain and logistics across globe bringing economic activity near to stand-still. Public finances have been negatively affected. Despite major developments in pharmaceuticals, the spread of infectious diseases is rising across globe due to globalization, increased trade and travel, urbanisation, reviving pathogens and improper use antibiotics etc. The hospital operational activities witnessed a vast impact on account of disruptions in supply chain of ADC’s across globe. As per American Cancer Society report in 2021, there was 52% decline in diagnosis of breast cancer cases, while 25% reduction in diagnosis of pancreatic cancer during the period of March to April 2020.
About We Market Research
We Market Research is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.
Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. We Market Research is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.
Contact Us:
We Market Research
Phone: +1(929)-450-2887
Email: [email protected]
